Research
Hormonal
Surgical removal of adipose tissue and specific genetic modifications (e.g., deletion of diacylglycerol acyltransferase 1) extend lifespan in rodents.
In rodents, removing fat or modifying specific fat-synthesis genes extends life. This highlights the critical role of adipose tissue in aging. For humans, this suggests that managing body fat levels is crucial for healthspan, though surgical removal is not a viable longevity strategy.
GoodSupportsHIGH confidence
The surgical removal of adipose tissue extends lifespan in rats, and increased expression of apolipoprotein D enhances survival in both flies and mice. Mouse lifespan can be additionally extended by the genetic deletion of diacylglycerol acyltransferase 1...
Why this rating
Direct interventional evidence in mammals (rats/mice) with reported lifespan increases.
Source
The role of lipid metabolism in aging, lifespan regulation, and age‐related disease
Adiv A. Johnson et al. · Aging Cell · 2019
DOI 10.1111/acel.13048
narrative_reviewCited 461×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genetic or pharmacological interventions that impair lipid synthesis (specifically ceramide and sphingolipid pathways) or enhance lipid hydrolysis (lysosomal lipases) extend lifespan in model organisms including nematodes and fruit flies.Moderate
- Specific blood lipid profiles (e.g., levels of triglycerides, lysophosphatidylcholine, and apolipoprotein E alleles) correlate with human aging and exceptional longevity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →